Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Journal: Current medical research and opinion
Published: August 26, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma.
Journal: JAMA network open
Published: May 21, 2026
Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study.
Journal: Research and practice in thrombosis and haemostasis
Published: May 06, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
Journal: Journal of comparative effectiveness research
Published: March 12, 2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.
Journal: Journal of comparative effectiveness research
Published: January 27, 2026
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy.
Journal: Future oncology (London, England)
Published: January 19, 2026
Real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC).
Journal: Future oncology (London, England)
Published: January 08, 2026
Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.
Journal: British journal of haematology
Published: January 06, 2026
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study.
Journal: Oncology and therapy
Published: November 20, 2025
Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?
Journal: Clinical genitourinary cancer
Published: October 03, 2025
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab.
Journal: JAMA network open
Published: June 09, 2025
Last Updated: 09/26/2026